14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today FATE ranks #16695 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Fate Therapeutics Stock Forecast NASDAQ:FATE

$48.00 (-8.75%)

Volume: 1M

Closed: Dec 03, 2021

Hollow Logo Score: -6.066

Fate Therapeutics Stock Forecast

$48.00 (-8.75%)

Volume: 1M

Closed: Dec 03, 2021

Score Hollow Logo -6.066

Fate Therapeutics Stock Forecast NASDAQ:FATE

Price Target and Analyst Ratings

Most Recent Rating

On Nov 08, 2021 "Citigroup" gave "" rating for FATE. The price target was changed from $60.88 to 0.9%.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-11-08 Upgraded by Citigroup $60.79 $60.88→0.9%
2021-11-08 $118.00 - $115.00 Target Lowered by SVB Leerink $60.79 $62.54+1.8%
2021-11-05 $90.00 - $60.00 Target Lowered by Roth Capital $61.42 $61.70+3.4%
2021-08-26 $77.00 Initiated by Morgan Stanley $71.25 $72.94+2.0%
2021-08-23 $121.00 Reiterated by HC Wainwright $72.27 $70.22+4.8%
2021-08-05 $120.00 - $118.00 Target Lowered by SVB Leerink $95.54 $89.73+4.7%
2021-08-05 $120.00 - $121.00 Target Raised by HC Wainwright $95.54 $89.73+4.7%
2021-07-09 $116.00 Reiterated by Stifel Nicolaus $90.45 $90.45+3.6%
2021-06-07 Neutral - Buy Upgraded by HC Wainwright $77.00 $120.00
2021-05-14 Outperform - Neutral Downgraded by Wedbush $76.70
2021-05-07 Neutral - Outperform Upgraded by Wedbush $76.49 $88.00
2021-04-26 Buy Initiated by Jefferies Financial Group $92.01 $145.00
2021-03-18 Outperform Target Raised by SVB Leerink $85.97 $58.00 → $121.00
2021-03-12 Outperform Target Raised by SVB Leerink $93.99 $58.00 → $121.00
2021-03-10 Overweight Target Raised by Wells Fargo & Company $89.85 $84.00 → $130.00
2021-03-04 Overweight Target Raised by Wells Fargo & Company $83.14 $84.00 → $130.00
2021-03-04 Outperform - Neutral Reiterated by Wedbush $83.14
2021-03-03 Buy Target Raised by Mizuho $88.49 $88.00 → $109.00
2021-03-03 Overweight Target Raised by Cantor Fitzgerald $88.49 $86.00 → $98.00
2021-02-26 Outperform - Neutral Downgraded by Wedbush $89.72
2021-02-26 Buy Initiated by Bank of America $89.72 $115.00
2021-02-26 Target Raised by Truist $89.72 $85.00 → $135.00
2021-02-25 Overweight Target Raised by Cantor Fitzgerald $86.27 $86.00 → $98.00
2021-02-25 Buy Target Raised by Mizuho $86.27 $88.00 → $109.00
2021-02-25 Target Raised by Roth Capital $86.27 $30.00 → $90.00
2021-02-17 Overweight Target Raised by Piper Sandler $103.22 $99.00 → $116.00
2021-02-11 Buy - Neutral Downgraded by Citigroup $102.50
2021-01-27 Neutral Reiterated by HC Wainwright $87.52 $108.00
2021-01-25 Market Perform Target Raised by BMO Capital Markets $96.14 $57.00 → $88.00
2021-01-19 Outperform Reiterated by Oppenheimer $114.31 $70.00 → $135.00
2021-01-15 Positive - Overweight Target Raised by Barclays $113.59 $110.00 → $130.00
2020-12-21 Buy Target Raised by Stifel Nicolaus $94.06 $79.00 → $118.00
2020-12-17 Overweight Target Raised by Barclays $92.25 $80.00 → $110.00
2020-12-08 Buy Target Raised by Mizuho $91.60 $40.00 → $88.00
2020-12-07 Outperform Target Raised by SVB Leerink $83.77 $34.00 → $58.00
2020-12-07 Target Raised by Smith Barney Citigroup $83.77 $63.00 → $76.00
2020-12-07 Outperform Reiterated by Oppenheimer $83.77 $60.00 → $70.00
2020-12-07 Overweight Reiterated by Piper Sandler $83.77 $71.00 → $99.00
2020-12-07 Target Raised by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $83.77 $63.00 → $76.00
2020-12-07 Overweight Target Raised by Wells Fargo & Company $83.77 $61.00 → $84.00
2020-12-07 Outperform Target Raised by Wedbush $83.77 $55.00 → $88.00
2020-12-07 Outperform Target Raised by Oppenheimer $83.77 $60.00 → $70.00
2020-12-07 Overweight Target Raised by Piper Sandler $83.77 $71.00 → $99.00
2020-12-07 Market Perform Target Raised by BMO Capital Markets $83.77 $43.00 → $57.00
2020-12-02 Overweight Target Raised by Barclays $60.53 $60.00 → $70.00
2020-11-24 Target Raised by Truist $55.27 $40.00 → $65.00
2020-11-09 Target Raised by Smith Barney Citigroup $50.69 $40.00 → $63.00
2020-11-09 Target Raised by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $50.69 $40.00 → $63.00
2020-11-08 Outperform Target Raised by Oppenheimer $48.28 $40.00 → $60.00
2020-11-06 Overweight Target Raised by Wells Fargo & Company $48.28 $38.00 → $61.00
2020-11-06 Market Perform Target Raised by BMO Capital Markets $48.28 $29.00 → $43.00
2020-11-06 Overweight Target Raised by Piper Sandler $48.28 $59.00 → $71.00
2020-10-15 Overweight Target Raised by Barclays $48.10 $40.00 → $60.00
2020-10-15 Overweight Reiterated by Barclays $48.10 $40.00 → $60.00
2020-08-13 Overweight Target Raised by Cantor Fitzgerald $35.01 $32.00 → $40.00
2020-08-06 Buy Reiterated by HC Wainwright $33.42 $42.00
2020-08-06 Buy Reiterated by Oppenheimer $33.42 $40.00
2020-06-09 Target Lowered by Piper Sandler $32.72 $63.00 → $59.00
2020-05-13 Buy Initiated by HC Wainwright $27.44 $42.00
2020-05-12 Market Perform Target Raised by BMO Capital Markets $28.75 $28.00 → $29.00

FATE Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -22.10% during the next 3 months and, with a 90% probability hold a price between $34.93 and $44.02 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2021-12-07 $44.58 $50.42 $56.25
2021-12-08 $44.33 $50.16 $55.99
2021-12-09 $44.07 $49.90 $55.73
2021-12-10 $43.81 $49.64 $55.47
2021-12-13 $43.55 $49.38 $55.21
2021-12-14 $43.29 $49.12 $54.95
2021-12-15 $43.03 $48.86 $54.70
2021-12-16 $42.77 $48.61 $54.44
2021-12-17 $42.52 $48.35 $54.18
2021-12-20 $42.26 $48.09 $53.92
2021-12-21 $42.00 $47.83 $53.66
2021-12-22 $41.74 $47.57 $53.40
2021-12-23 $41.48 $47.31 $53.14
2021-12-27 $41.22 $47.05 $52.89
2021-12-28 $40.96 $46.80 $52.63
2021-12-29 $40.71 $46.54 $52.37
2021-12-30 $40.45 $46.28 $52.11
2021-12-31 $40.19 $46.02 $51.85
2022-01-03 $39.93 $45.76 $51.59
2022-01-04 $39.67 $45.50 $51.33
2022-01-05 $39.41 $45.24 $51.07
2022-01-06 $39.15 $44.98 $50.82
2022-01-07 $38.89 $44.73 $50.56
2022-01-10 $38.64 $44.47 $50.30
2022-01-11 $38.38 $44.21 $50.04
2022-01-12 $38.12 $43.95 $49.78
2022-01-13 $37.86 $43.69 $49.52
2022-01-14 $37.60 $43.43 $49.26
2022-01-17 $37.34 $43.17 $49.01
2022-01-18 $37.08 $42.92 $48.75

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. Its novel ex vivo cell programming approach applies to modulate the therapeutic function and direct the fate of immune cells. The company’s lead product candidate is ProTmune, a programmed immuno-regulatory cell therapy that is in clinical development stage for the p... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT